Kajian Literatur : Tinjauan Terapi Kardioprotektan untuk Penanganan Kardiotoksisitas Kemoterapi Antrasiklin
DOI:
https://doi.org/10.20527/jps.v12i1.19910Kata Kunci:
Antrasiklin, Kardiotoksisitas, Terapi, Kardioprotektan, FarmakologiAbstrak
Saat ini telah banyak diteliti mengenai beberapa agen farmakologi untuk terapi penanganan kardiotoksisitas antrasiklin. Namun, dibutuhkan kajian lebih lanjut terhadap strategi terapi kardiotoksisitas antrasiklin tersebut dari segi kefarmasian untuk memperkaya referensi sebagai dasar praktek klinis untuk tatalaksana kardiotoksisitas, terutama di negara berkembang. Kajian literatur ini bertujuan mengkaji lebih mendalam terkait kardioprotektan dari aspek mekanisme kerja, karakteristik farmakokinetik, serta dari evidence based medicine yang ada. Kajian literatur secara komprehensif dilakukan berdasarkan penelusuran jurnal ilmiah melalui penelusuran elektronik dengan kata kunci kombinasi “cardioprotectiveâ€, “anthracyclineâ€, dan “cardiotoxicityâ€. Dari seluruh artikel yang diperoleh, didapatkan 39 artikel yang dapat dikaji lebih lanjut, yakni artikel mengenai kardiotoksisitas antrasiklin, serta penelitian dan bukti ilmiah mengenai agen-agen farmakologi yang diteliti bersifat kardioprotektif. Kesimpulan dari tinjauan ini adalah beberapa agen farmakologis telah menunjukkan luaran yang baik pada beberapa parameter kardiotoksisitas, namun penelitian tingkat lanjut dengan skala lebih besar dan waktu  follow up yang lebih lama masih diperlukan terutama dengan sampel domestik agar dapat diperoleh konklusi yang dapat diaplikasikan secara klinis pada masyarakat Indonesia.Referensi
Abdel-Qadir, H., Bobrowski, D., Zhou, L., Austin, P. C., Calvillo-Argüelles, O., Amir, E., Lee, D. S., & Thavendiranathan, P. (2021). Statin exposure and risk of heart failure after anthracycline-or trastuzumab-based chemotherapy for early breast cancer: A propensity score‒matched cohort study. Journal of the American Heart Association, 10(2), 1–12. https://doi.org/10.1161/JAHA.119.018393
Acar, Z., Kale, A., Turgut, M., Demircan, S., Durna, K., Demir, S., Meriç, M., & Aǧaç, M. T. (2011). Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy. Journal of the American College of Cardiology, 58(9), 988–989. https://doi.org/10.1016/j.jacc.2011.05.025
Alizadehasl, A., Ghadimi2, N., Kaveh, S., Maleki, M., Ghavamzadeh, A., Noohi, F., Hosseinif, H., & Ard. (2020). Prevention of anthracycline‑induced cardiotoxicity : a systematic review and meta analysis. Internationl Journal of Clinical Pharmacy. https://doi.org/10.1007/s11096-020-01146-6
Angsutararux, P., Luanpitpong, S., & Issaragrisil, S. (2015). Chemotherapy-Induced Cardiotoxicity : Overview of the Roles of Oxidative Stress. Oxidative Medicine and Cellular Longevity. https://doi.org/10.1155/2015/795602
Balitbangkes Kemenkes RI. (2018). Laporan Nasional Riset Kesehatan Dasar. In Lembaga Penerbit Badan Penelitian dan Pengembangan Kesehatan.
BC Cancer. (2017). DRUG NAME : Dexrazoxane. BC Cancer Agency Cancer Drug Manual, 1–5.
Caspani, F., Tralongo, A. C., Campiotti, L., Asteggiano, R., Guasti, L., & Squizzato, A. (2020). Prevention of anthracycline‑induced cardiotoxicity : a systematic review and meta-analysis. Internal and Emergency Medicine. https://doi.org/10.1007/s11739-020-02508-8
ÄŒiburienÄ—, E., AidietienÄ—, S., Å ÄerbickaitÄ—, G., SadauskienÄ—, E., SudaviÄienÄ—, D., BaltruÅ¡keviÄienÄ—, E., BrasiÅ«nienÄ—, B., DrobnienÄ—, M., & ÄŒelutkienÄ—, J. (2023). Ivabradine for the Prevention of Anthracycline-Induced Cardiotoxicity in Female Patients with Primarily Breast Cancer: A Prospective, Randomized, Open-Label Clinical Trial. Medicina (Lithuania), 59(12). https://doi.org/10.3390/medicina59122140
Cid-Conde, L., & López-Castro, J. (2021). Pharmacokinetic Aspects of Statins. Cardiovascular Risk Factors in Pathology, February. https://doi.org/10.5772/intechopen.91910
Curigliano, G., Lenihan, D., Fradley, M., Ganatra, S., Barac, A., Blaes, A., Herrmann, J., Porter, C., Lyon, A. R., Lancellotti, P., Patel, A., DeCara, J., Mitchell, J., Harrison, E., Moslehi, J., Witteles, R., Calabro, M. G., Orecchia, R., de Azambuja, E., … Jordan, K. (2020). Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Annals of Oncology, 31(2), 171–190. https://doi.org/10.1016/j.annonc.2019.10.023
D’Amario, D., Laborante, R., Bianchini, E., Galli, M., Ciliberti, G., Mennuni, M., & Patti, G. (2023). Statins as preventive therapy for anthracycline cardiotoxicity: a meta-analysis of randomized controlled trials. International Journal of Cardiology, 391(March). https://doi.org/10.1016/j.ijcard.2023.131219
D’Onofrio, N., Sardu, C., Trotta, M. C., Scisciola, L., Turriziani, F., Ferraraccio, F., Panarese, I., Petrella, L., Fanelli, M., Modugno, P., Massetti, M., Marfella, L. V., Sasso, F. C., Rizzo, M. R., Barbieri, M., Furbatto, F., Minicucci, F., Mauro, C., Federici, M., … Marfella, R. (2021). Sodium-glucose co-transporter2 expression and inflammatory activity in diabetic atherosclerotic plaques: Effects of sodium-glucose co-transporter2 inhibitor treatment. Molecular Metabolism, 54(September), 101337. https://doi.org/10.1016/j.molmet.2021.101337
Dabour, M. S., George, M. Y., Daniel, M. R., Blaes, A. H., & Zordoky, B. N. (2024). The Cardioprotective and Anticancer Effects of SGLT2 Inhibitors: JACC: CardioOncology State-of-the-Art Review. JACC: CardioOncology, 6(2), 159–182. https://doi.org/10.1016/j.jaccao.2024.01.007
Dallapellegrina, L., Sciatti, E., & Vizzardi, E. (2020). Ivabradine and endothelium: an update. Therapeutic Advances in Cardiovascular Disease, 14, 1–6. https://doi.org/10.1177/1753944720934937
de Baat, E. C., Mulder, R. L., Armenian, S., Feijen, E. A. M., Grotenhuis, H., Hudson, M. M., Mavinkurve-Groothuis, A. M. C., Kremer, L. C. M., & van Dalen, E. C. (2022). Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.CD014638.pub2
El-Naggar, A. E., El-Gowilly, S. M., & Sharabi, F. M. (2018). Possible ameliorative effect of ivabradine on the autonomic and left ventricular dysfunction induced by doxorubicin in male rats. In Journal of Cardiovascular Pharmacology (Vol. 72, Issue 1). https://doi.org/10.1097/FJC.0000000000000586
European Medicines Agency. (2024). ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS : Procoralan (Ivabradine).
Felix, N., Nogueira, P. C., Silva, I. M., Costa, T. A., Campello, C. A., Stecca, C., & Lopes, R. D. (2024). Cardio-protective effects of statins in patients undergoing anthracycline-based chemotherapy: An updated meta-analysis of randomized controlled trials. European Journal of Internal Medicine, May. https://doi.org/10.1016/j.ejim.2024.04.007
Förstermann, U., & Münzel, T. (2006). Endothelial nitric oxide synthase in vascular disease: From marvel to menace. Circulation, 113(13), 1708–1714. https://doi.org/10.1161/CIRCULATIONAHA.105.602532
Gammella, E., Maccarinelli, F., Buratti, P., Recalcati, S., & Cairo, G. (2014). The role of iron in anthracycline cardiotoxicity. Front. Pharmacol., 5(1–6). https://doi.org/10.3389/fphar.2014.00025
Ganatra, S., Nohria, A., Shah, S., Groarke, J. D., Sharma, A., Venesy, D., Patten, R., Gunturu, K., Zarwan, C., Neilan, T. G., Barac, A., Hayek, S. S., Dani, S., Solanki, S., Mahmood, S. S., & Lipshultz, S. E. (2019). Upfront dexrazoxane for the reduction of anthracycline-induced cardiotoxicity in adults with preexisting cardiomyopathy and cancer: A consecutive case series. Cardio-Oncology, 5(1), 1–12. https://doi.org/10.1186/s40959-019-0036-7
Gao, Y., Wang, R., Jiang, J., Hu, Y., Li, H., & Wang, Y. (2023). ACEI/ARB and beta-blocker therapies for preventing cardiotoxicity of antineoplastic agents in breast cancer: a systematic review and meta-analysis. In Heart Failure Reviews (Vol. 28, Issue 6, pp. 1405–1415). https://doi.org/10.1007/s10741-023-10328-z
He, D., Hu, J., Li, Y., & Zeng, X. (2022). Preventive use of beta-blockers for anthracycline-induced cardiotoxicity: A network meta-analysis. Frontiers in Cardiovascular Medicine, 9. https://doi.org/10.3389/fcvm.2022.968534
Hussen, N. H., Muhammed, G. O., Yassin, A. Y., Esmail, P. A., & Salih, R. R. (2022). Anthracycline in Medicinal Chemistry : Chemistry , SARs , Mechanism of Cardiotoxicity and Preventive Strategies. Medicinal Chemistry ISSN:, 12(8), 1–12. https://doi.org/10.37421/2161-0444.2022.12.
Ibrahim, A. N., & Mousa, A. (2013). Effects of Ivabradine on Cardiotoxicity Induced by Doxorubicin Treatment in Rats. The Medical Journal of Cairo University, 81.
Jaiswal, V., Ang, S. P., Deb, N., Hanif, M., Batra, N., Kanagala, S. G., Vojjala, N., Rajak, K., Roy, P., & Sharath, M. (2024). Association between Statin Use and Chemotherapy-Induced Cardiotoxicity : A Meta-Analysis. Medicina. https://doi.org/https://doi.org/10.3390/medicina60040580
Kerr, D. J., Haller, D. G., & Verweij, J. (2016). Principles of chemotherapy. In Oxford Textbook of Oncology (3rd ed., p. 186). Oxford University Press. https://doi.org/10.1093/med/9780199656103.001.0001
Leenders, G. J., Smeets, M. B., Van Den Boomen, M., Berben, M., Nabben, M., Van Strijp, D., Strijkers, G. J., Prompers, J. J., Arslan, F., Nicolay, K., & Vandoorne, K. (2018). Statins Promote Cardiac Infarct Healing by Modulating Endothelial Barrier Function Revealed by Contrast-Enhanced Magnetic Resonance Imaging. Arteriosclerosis, Thrombosis, and Vascular Biology, 38(1), 186–194. https://doi.org/10.1161/ATVBAHA.117.310339
Li, J., Lee, A. R. Y. Bin, Tariq, A., Lau, G., Yau, C. E., Tan, L. L., Tyebally, S. M., Lee, M. X., Koo, C. Y., & Sia, C. H. (2023). Comparing Renin-Angiotensin-Aldosterone Blockade Regimens for Long-Term Chemotherapy-Related Cardiac Dysfunction: A Network Meta-Analysis. Cardiovascular Drugs and Therapy. https://doi.org/10.1007/s10557-023-07457-w
Lipshultz, S. E., Lipsitz, S. R., Kutok, J. L., Miller, T., Steven, C., Neuberg, D. S., Stevenson, K. E., Fleming, M. D., Sallan, S. E., Franco, V. I., Henkel, J. M., Asselin, B. L., Athale, U. H., Clavell, L. A., Michon, B., Laverdiere, C., Larsen, E., Kelly, K. M., & Silverman, L. B. (2013). Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high risk leukemia. Cancer. https://doi.org/10.1002/cncr.28256.Impact
Macedo, A. V. S., Hajjar, L. A., Lyon, A. R., Nascimento, B. R., Putzu, A., Rossi, L., Costa, R. B., Landoni, G., Nogueira-Rodrigues, A., & Ribeiro, A. L. P. (2019). Efficacy of Dexrazoxane in Preventing Anthracycline Cardiotoxicity in Breast Cancer. JACC: CardioOncology, 1(1), 68–79. https://doi.org/10.1016/j.jaccao.2019.08.003
Marfella, R., Scisciola, L., D’Onofrio, N., Maiello, C., Trotta, M. C., Sardu, C., Panarese, I., Ferraraccio, F., Capuano, A., Barbieri, M., Balestrieri, M. L., Napoli, C., & Paolisso, G. (2022). Sodium-glucose cotransporter-2 (SGLT2) expression in diabetic and non-diabetic failing human cardiomyocytes. Pharmacological Research, 184(July), 106448. https://doi.org/10.1016/j.phrs.2022.106448
Massaro, M., Zampolli, A., Scoditti, E., Carluccio, M. A., Storelli, C., Distante, A., & De Caterina, R. (2010). Statins inhibit cyclooxygenase-2 and matrix metalloproteinase-9 in human endothelial cells: Anti-angiogenic actions possibly contributing to plaque stability. Cardiovascular Research, 86(2), 311–320. https://doi.org/10.1093/cvr/cvp375
Morelli, M. B., Bongiovanni, C., Da Pra, S., Miano, C., Sacchi, F., Lauriola, M., & D’Uva, G. (2022). Cardiotoxicity of Anticancer Drugs: Molecular Mechanisms and Strategies for Cardioprotection. Frontiers in Cardiovascular Medicine, 9(April). https://doi.org/10.3389/fcvm.2022.847012
Müller-werdan, U., Stöckl, G., & Werdan, K. (2016). Advances in the management of heart failure : the role of ivabradine. Vascular Health and Risk Management, 12, 453–470. https://doi.org/10.1016/j.pcad.2024.01.006
Obasi, M., Abovich, A., Vo, J. B., Gao, Y., Papatheodorou, S. I., Nohria, A., Asnani, A., & Partridge, A. H. (2021). Statins to mitigate cardiotoxicity in cancer patients treated with anthracyclines and/or trastuzumab: a systematic review and meta-analysis. Cancer Causes and Control, 32(12), 1395–1405. https://doi.org/10.1007/s10552-021-01487-1
Oh, C. M., Cho, S., Jang, J. Y., Kim, H., Chun, S., Choi, M., Park, S., & Ko, Y. G. (2019). Cardioprotective potential of an SGLT2 inhibitor against doxorubicin-induced heart failure. Korean Circulation Journal, 49(12), 1183–1195. https://doi.org/10.4070/kcj.2019.0180
Omland, T., Heck, S. L., & Gulati, G. (2022). The Role of Cardioprotection in Cancer Therapy Cardiotoxicity - JACC: CardioOncology State-of-the-Art Review. JACC: CardioOncology, 4(1), 19–37. https://doi.org/10.1016/j.jaccao.2022.01.101
Paolisso, P., Bergamaschi, L., Gragnano, F., Gallinoro, E., Cesaro, A., Sardu, C., Mileva, N., Foà , A., Armillotta, M., Sansonetti, A., Amicone, S., Impellizzeri, A., Esposito, G., Nuccia, M., Andrea, O. J., Casella, G., Mauro, C., Vassilev, D., Galie, N., … Barbato, E. (2023). Outcomes in diabetic patients treated with SGLT2-Inhibitors with acute myocardial infarction undergoing PCI: The SGLT2-I AMI PROTECT Registry. Pharmacological Research, 187(November 2022). https://doi.org/10.1016/j.phrs.2022.106597
Pubchem. (2024). Compound Summary : Dexrazoxane. National Library of Medicine. https://pubchem.ncbi.nlm.nih.gov/compound/Dexrazoxane
Rossi, S. (2014). Australian Medicines Handbook.
Sabatino, J., De Rosa, S., Tammè, L., Iaconetti, C., Sorrentino, S., Polimeni, A., Mignogna, C., Amorosi, A., Spaccarotella, C., Yasuda, M., & Indolfi, C. (2020). Empagliflozin prevents doxorubicin-induced myocardial dysfunction. Cardiovascular Diabetology, 19(1), 66. https://doi.org/10.1186/s12933-020-01040-5
Sallustio, B. C., & Boddy, A. V. (2021). Is there scope for better individualisation of anthracycline cancer chemotherapy? British Journal of Clinical Pharmacology, 87(2), 295–305. https://doi.org/10.1111/bcp.14628
Scheen, A. J. (2015). Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease. Clinical Pharmacokinetics, 54(7), 691–708. https://doi.org/10.1007/s40262-015-0264-4
Smith, L. A., Cornelius, V. R., Plummer, C. J., Levitt, G., Verrill, M., Canney, P., & Jones, A. (2010). Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials. BMC Cancer, 10. https://doi.org/10.1186/1471-2407-10-337
Tabowei, G., Dadzie, S. K., Perswani, P., Nawaz, S., Kaur, M., Moqattash, M., Wei, C. R., & Hirani, S. (2024). Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Preventing Heart Failure in Patients Receiving Anthracycline-Based Cancer Therapy: A Systematic Review and Meta-Analysis. Cureus, 16(5). https://doi.org/10.7759/cureus.60086
Tantawy, M., Pamittan, F. G., & Singh, S. (2021). Epigenetic Changes Associated With Anthracycline- Induced Cardiotoxicity. Clinical and Translational Science, 14, 36–46. https://doi.org/10.1111/cts.12857
Tokarska-schlattner, M., Zaugg, M., Zuppinger, C., Wallimann, T., &
Schlattner, U. (2006). New insights into doxorubicin-induced cardiotoxicity : The critical role of cellular energetics. 41, 389–405. https://doi.org/10.1016/j.yjmcc.2006.06.009
van Dalen, E. C., Caron, H. N., Dickinson, H. O., & Kremer, L. C. M. (2016). Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.CD003917.pub4
Varghese, S. S., Eekhoudt, C. R., & Jassal, D. S. (2021). Mechanisms of anthracycline-mediated cardiotoxicity and preventative strategies in women with breast cancer. Molecular and Cellular Biochemistry, 476(8), 3099–3109. https://doi.org/10.1007/s11010-021-04152-y
Vasyuk, Y. V., Nesvetov, V. V., Shkolnik, E. L., Shkolnik, L. D., Varlan, G. V., Gendlin, G. E., & Emelina, E. I. (2017). Possibilities Of Ivabradine, A Selective Inhibitor Of Ion F-Channels of Sinus Node, in Prevention of Anthracycline Cardiotoxicity in Patients With Breast Cancer. Rational Pharmacotherapy in Cardiology, 13(2). https://doi.org/doi.org/10.20996/1819-6446-2017-13-2-184-190
Venkatesh, P., & Kasi, A. (2023). Anthracyclines. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK538187/
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., Bhatt, D. L., Leiter, L. A., McGuire, D. K., Wilding, J. P. H., Ruff, C. T., Gause-Nilsson, I. A. M., Fredriksson, M., Johansson, P. A., Langkilde, A.-M., & Sabatine, M. S. (2019). Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine, 380(4), 347–357. https://doi.org/10.1056/nejmoa1812389
Wu, B. Bin, Leung, K. T., & Poon, E. N. (2022). Mitochondrial-Targeted Therapy for Doxorubicin-Induced Cardiotoxicity. International Journal of Molecular Sciences, 23(1912). https://doi.org/https://doi.org/10.3390/ijms23031912
Yang, J., Liu, Y., Fan, X., Li, Z., & Cheng, Y. (2014). A pathway and network review on beta-adrenoceptor signaling and beta blockers in cardiac remodeling. Heart Failure Reviews, 19(6), 799–814. https://doi.org/10.1007/s10741-013-9417-4
Zhou, Q., & Liao, J. (2009). Statins and Cardiovascular Diseases: From Cholesterol Lowering to Pleiotropy. Current Pharmaceutical Design, 15(5), 467–478. https://doi.org/10.2174/138161209787315684
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Inzucchi, S. E. (2015). Empagliflozin, Cardiovascular Outcomes, and Mortality in type 2 diabetes. The New England Journal of Medicine, 373, 2117–2128. https://doi.org/10.1056/nejmoa1504720
Zisaki, A., Miskovic, L., & Hatzimanikatis, V. (2014). Antihypertensive Drugs Metabolism: An Update to Pharmacokinetic Profiles and Computational Approaches. Current Pharmaceutical Design, 21(6), 806–822. https://doi.org/10.2174/1381612820666141024151119
##submission.downloads##
Diterbitkan
Terbitan
Bagian
Lisensi
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
.jpg)
